In a regional shortage of long‑acting insulin pens, how should I allocate the limited pens between an 82‑year‑old patient with multiple comorbidities and limited life expectancy and a 32‑year‑old single parent with type 1 diabetes and dependent children?

Allocation of Long-Acting Insulin Pens During Regional Shortage

Allocate the long-acting insulin pens to the 32-year-old single parent with Type 1 diabetes, as this decision prioritizes both immediate mortality risk and long-term quality of life for dependent children while the 82-year-old patient can be safely managed with alternative insulin delivery methods.

Clinical Rationale for Allocation Decision

Mortality and Morbidity Considerations

The 32-year-old with Type 1 diabetes faces absolute insulin dependence and life-threatening risk without appropriate insulin delivery. Type 1 diabetes patients require continuous insulin therapy to prevent diabetic ketoacidosis and death 1. The younger patient has decades of potential life years at stake, while the 82-year-old with multiple comorbidities and limited life expectancy has significantly reduced life years remaining 2.

• Providers demonstrably treat elderly patients with limited life expectancy less aggressively, with lower rates of treatment intensification (20.9% vs 28.6%) and acceptance of less stringent glycemic targets 2
• Five-year mortality in elderly patients with diabetes and multiple comorbidities is five times higher than those without limited life expectancy 2

Quality of Life Impact

The allocation decision must account for the dependent children who rely on the 32-year-old parent's survival and functional capacity. Loss of glycemic control or insulin access in the younger patient would:

• Compromise the parent's ability to care for dependent children
• Create potential orphaning risk if severe complications or death occur
• Impact multiple lives beyond the individual patient 1

The elderly patient's quality of life considerations, while important, affect primarily the individual rather than dependent family members 1.

Alternative Management for the 82-Year-Old Patient

Insulin Syringes as Viable Alternative

Traditional insulin syringes remain a safe and effective delivery method that can achieve glycemic targets in elderly patients. 1, 3

• Syringes are significantly less expensive than pens and widely available even during shortages 3
• Multiple studies confirm equivalent glycemic outcomes between syringes and pens 1
• The 2022 ADA Standards acknowledge that "insulin syringes may be used for insulin delivery with consideration of patient preference" 1

Practical Implementation for Elderly Patient

If the 82-year-old has dexterity or vision limitations, implement these strategies:

• Arrange for caregiver assistance with syringe preparation and administration 1
• Pre-fill syringes in advance (can be stored and rolled before use) 1
• Use larger syringe sizes (1 mL) with clearer markings for easier visualization 1
• Consider insulin injection aids if manual dexterity is impaired 1, 3

Adjusted Glycemic Targets for Elderly Patient

Less stringent glycemic control is clinically appropriate for elderly patients with limited life expectancy and multiple comorbidities. 1, 2

• Higher HbA1c targets (8.0-8.5%) are acceptable and reduce hypoglycemia risk 1
• Avoiding hypoglycemia takes priority over tight glycemic control in this population 1
• Once-daily basal insulin regimens minimize complexity and hypoglycemia risk 1

Common Pitfalls to Avoid

Do not assume pens are medically necessary for the elderly patient. While pens offer convenience, they are not clinically superior for achieving glycemic targets when proper technique is used with syringes 1, 4. The 2021 randomized trial in elderly patients showed that while pens produced slightly greater HbA1c reduction (-1.94% vs -1.04%), both groups achieved clinically acceptable control, and there was no difference in hypoglycemia rates, adherence, or quality of life 4.

Do not overlook the absolute insulin requirement difference. The Type 1 diabetes patient has zero endogenous insulin production and faces immediate life-threatening risk without insulin delivery 1. The elderly Type 2 patient (if Type 2) likely retains some endogenous insulin production and has more therapeutic flexibility 1.

Ensure proper training for syringe use. The elderly patient and any caregivers must receive education on proper insulin drawing technique, air bubble removal, injection site rotation, and dose verification 1. Annual examination of injection sites is mandatory 1.

Documentation and Communication

Document the allocation decision with clear clinical justification:

• Note the Type 1 diabetes diagnosis and absolute insulin dependence in the younger patient
• Document limited life expectancy and multiple comorbidities in the elderly patient
• Record the availability and clinical equivalence of syringe-based insulin delivery
• Explain the broader quality of life impact on dependent children 1

Communicate transparently with both patients about the shortage, the allocation rationale prioritizing mortality risk and quality of life, and the plan to ensure both patients receive safe, effective insulin therapy through appropriate delivery methods 1.